Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B

Journal of Urology

Volumn 158, Issue 6, 1997, Pages 2311-2315

  Downs, Tracy M ^b   Szilvasi, Akos ^b   O'Donnell, Michael A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

BCG; Biocompatibility; Bladder cancer; Immunotherapy; Interferon alpha

Indexed keywords

BCG VACCINE; RECOMBINANT ALPHA2B INTERFERON; THERACYS; UNCLASSIFIED DRUG;

ARTICLE; BIOCOMPATIBILITY; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG FORMULATION; HUMAN; HUMAN CELL; INTRAVESICAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030727642     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)68241-7     Document Type: Article

References (45)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1996. CA Cancer J. Clin., 46: 5, 1996.
2. O'Donnell, M. A. and DeWolf, W. C.: Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer: New prospects for an old warhorse. Surg. Oncol. Clin. N. Am., 4: 189, 1995.
3. Morales, A., Eidinger, D. and Bruce, A. W.: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumours. J. Urol., 116: 180, 1976.
4. Comeri, G. C., Belvisi, P., Conti, G., Cretarola, E., Duvia, R., Furgoni, R., Gianneo, E. and Radice, G. P.: [Role of BCG in T1G3 bladder transitional cell carcinoma (TCC): our experience]. Arch. Ital. Urol. Androl., 68: 55, 1996.
5. Herr, H., Schwalb, D., Zhang, Z., Whitmore, W. and Oettgen, H.: Intravesical BCG for superficial bladder cancer (SBT): 10-year results of a prospective randomized trial (Meeting abstract). Urol. Int., suppl. 1, 47: 108, 1991.
6. Hurle, R., Graziotti, P., Ranieri, A., Losa, A., Micheli, E. and Lembo, A.: T1G3 transitional cell carcinoma of the bladder: our experience with 44 patients treated with intravesical BCG after TUR. Br. J. Urol., 75: 188, 1995.
7. Lamm, D. L.: BCG in perspective: advances in the treatment of superficial bladder cancer. Eur. Urol., suppl. 1, 27: 2, 1995.
8. Melekos, M. D., Zarakovitis, I. E., Fokaefs, E. D., Dandinis, K., Chionis, H., Bouropoulos, C. and Dauaher, H.: Intravesical bacillus Calmette-Guerin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours. Oncology, 53: 281, 1996.
9. Isaacs, A. and Lindenmann, J.: Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957 [classical article]. J. Interferon Res., 7: 429, 1987.
10. Sen, G. C. and Lengyel, P.: The Interferon system: a bird's eye view of its biochemistry. J. Biol. Chem., 267: 5017, 1992.
11. Baron, S., Tyring, S. K., Fleischmann, W. R., Coppenhaver, D. H., Niesel, D. W., Kimpel, G. R., Stanton, G. J. and Hughes, T. K.: The interferons: mechanisms of action and clinical applications. JAMA, 266: 1375, 1991.
12. Baron, S.: Mechanism of Recovery from Viral Infection. New York, NY: Academic Press Inc, vol., p., 1963.
13. Vedantham, S., Gamliel, H. and Golomb, H. M.: Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res., 52: 1056, 1992.
14. Grem, J. L., van Groeningen, C. J., Ismail, A. A., Johnston, P. G., Alexander, H. R. and Allegra, C. J.: The role of interferon-alpha as a modulator of fluorouracil and leucovorin. Eur. J. Cancer, 31A: 1316, 1995.
15. Nielsen, B., Madsen, P. S., Jensen, A. W., Hokland, P. and Hokland, M.: Interferon-alpha-induced changes in surface antigens in a hairy-cell leukemia (JOK-1), and a Burkitt's lymphoma cell line (Daudi) during in vitro culture. Eur. J. Haem., 48: 146, 1992.
16. Anthes, J. C., Zhan, Z., Gilchrest, H., Egan, R. W., Siegel, M. I. and Billah, M. M.: Interferon-alpha down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266. Biochem. J., 309: 175, 1995.
17. Torti, F. M., Shortliffe, L. D., Williams, R. D., Pitts, W. C., Kempson, R. L., Ross, I. C., Palmer, J., Meyers, F., Ferrari, M., Hannigan, J., Spiegel, R., McWhirter, K. and Freiha, F.: Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group study. J. Clin. Oncol., 6: 476, 1988.
18. Horoszewicz, J. S. and Murphy, G. P.: An assessment of the current use of human interferons in therapy of urological cancers. J. Urol., 142: 1173, 1989.
19. Kavoussi, L. R., Torrence, R. J., Gillen, D. P., Hudson, M. A., Haaff, E. O., Dresner, S. M., Ratliff, T. L. and Catalona, W. J.: Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J. Urol., 139: 935, 1988.
20. DeJager, R., Guinan, P. and Lamm, D.: Long-term complete remission in bladder carcinoma in situ with intravesical Tice bacillus Calmette Guerin. Urology, 38: 507, 1991.
21. Herr, H. W., Pinsky, C. M. and Whitmore, W. F.: Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J. Urol., 135: 265, 1986.
22. Glashan, R. W.: A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J. Urol., 144: 658, 1990.
23. Stricker, P., Pryor, K., Nicholson, T., Goldstein, D., Golovsky, D., Ferguson, R., Nash, P., Ehsman, S., Rumma, J., Mammen, G. and Penny, R.: Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology, 48: 957, 1996.
24. Riggs, D. R., Tarry, W. F., DeHaven, J. I., Sosnowski, J. and Lamm, D. L.: Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. J. Urol., 147: 212, 1992.
25. O'Donnell, M. A., Aldovini, A., Duda, R. B., Yang, H., Szilvasi, A., Young, R. A. and DeWolf, W. C.: Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Urology, 62: 2508, 1994.
26. Mosmann, T.: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55, 1983.
27. Yousefi, S., Escobar, M. R. and Gouldin, C. W.: A practical cytopathic effect/dye-uptake interferon assay for routine use in the clinical laboratory. Am. J. Clin. Pathol., 83: 735, 1985.
28. Kelley, D. R., Ratliff, T. L. and Catalona, W. J.: Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J. Urol., 134: 48, 1985.
29. Akaza, H., Hayashi, H., Takii, T., Oomoto, Y. and Onozaki, K.: BCG treatment of existing Ta, T1 tumours or carcinoma in situ of the bladder. Differential production of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and IL-1 receptor antagonist by human monocytes stimulated with Mycobacterium leprae and M. bovis BCG. Int. J. Lepr. Other Mycobact. Dis., 61: 609, 1993.
30. Groves, M. J.: Pharmaceutical characterization of Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine used for the treatment of superficial bladder cancer. J. Pharm. Sci., 82: 555, 1993.
31. Lugosi, L.: Standardized viability test required for preventive, immunomodulator and recombinant BCG vaccine. Dev. Biol. Stand., 77: 211, 1992.
32. Suzuki, K., Fukutomi, Y., Matsuoka, M., Torii, K., Hayashi, H., Takii, T., Oomoto, Y. and Onozaki ,K.: Differential production of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and IL-1 receptor antagonist by human monocytes stimulated with Mycobacterium leprae and M. bovis BCG. Int. J. Lepr. Other Mycobact. Dis., 61: 609, 1993.
33. Horii, A., Kyo, M., Asakawa, M., Yasumoto, R. and Maekawa, M.: Multidisciplinary treatment for bladder carcinoma-biological response modifiers and kampo medicines. Urol. Int., suppl. 1, 47: 108, 1991.
34. Calabresi, F. and Gamucci, T.: Biological response modifiers. Lung Cancer, suppl. 1, 12: S193, 1995.
35. Ratliff, T. L., Ritchey, J. K., Brandhorst, J. and Hanna, M. G., Jr.: Time-dependent aggregation of reconstituted BCG vaccine. J. Urol., 152: 2147, 1994.
36. Ratliff, T. L.: Role of the immune response in BCG for bladder cancer. Eur. Urol., 21: 17, 1992.
37. Bohle, A., Nowc, C., Ulmer, A. J., Musehold, J., Gerdes, J., Hofstetter, A. G. and Flad, H. D.: Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J. Urol., 144: 59, 1990.
38. Peuchmaur, M., Benoit, G., Vieillefond, A., Chevalier, A., Lemaigre, G., Martin, E. D. and Jardin, A.: Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus Calmette-Guerin. Urol. Res., 17: 299, 1989.
39. Keeley, F., Lattime, E. and McCue, P.: A comparison of the local immune response to intravesical alpha-interferon and bacillus Calmette-Guerin in patients with superficial bladder cancer. J. Urol., 151: 473A, 1994.
40. O'Donnell, M. A.: Unpublished data.
41. Jackson, A. M., Alexandrov, A. B., Prescott, S., James, K. and Chisholm, G. D.: Expression of adhesion molecules by bladder cancer cells: modulation by interferon-gamma and tumor necrosis factor-alpha. J. Urol., 148: 1583, 1992.
42. DeBoer, E. C., DeJong, W. H., Van Der Meijden, A. P. M., Steerenberg, P. A., Witjes, J. A., Vegt, P. D. J., Debruyne, F. M. J. and Ruitenberg, E. J.: Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guerin. Cancer Immunol. Immunother., 33: 411, 1991.
43. Loughman, B., Gibbons, A. and Targgart, M.: Modulation of mouse natural killer cell activity by interferon and two antiviral isocytosines. In: Proc. Int. Congr. Chemother. Curr. Chemother. Infect. Dis. (ed 11th), edited by Nelson, J. D. and Grassi, C., pp. 1398, Am. Soc. Microbiol., 1980.
44. Trotta, P.: Interferon alpha 2: Summary of pre-clinical data. Dev. Oncol., 27: 13, 1985.
45. Pryor, K., Russell, P. J., Stricker, P., Golovsky, D., French, P. and Penny, R.: Bacillus Calmette-Guerin (BCG) plus interferon alpha-2b (IFN alpha 2b) inhibit proliferation of human bladder cancer cell lines in vitro (Meeting abstract). Proc. Ann. Meet. Am. Assoc. Cancer Res., 36: A2809, 1995.